(Q43764398)

26 November 2017

title

Progenitor cells from patients with advanced phase chronic myeloid leukaemia respond to STI571 in vitro and in vivo (English)

1 reference

26 November 2017

1 reference

1 reference

Marley SB

1

1 reference

26 November 2017

Davidson RJ

2

1 reference

26 November 2017

Lewis JL

3

1 reference

26 November 2017

Nguyen DX

4

1 reference

26 November 2017

Eades A

5

1 reference

26 November 2017

Parker S

6

1 reference

26 November 2017

Goldman JM

7

1 reference

26 November 2017

Gordon MY

8

1 reference

26 November 2017

publication date

1 November 2001

1 reference

26 November 2017

1 reference

26 November 2017

volume

25

1 reference

26 November 2017

issue

11

1 reference

26 November 2017

page(s)

997-1002

1 reference

Cell biology of CML cells

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900066-2

7 January 2021

The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900066-2

7 January 2021

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900066-2

7 January 2021

Leukemia drug heralds molecularly targeted era

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900066-2

7 January 2021

The nuclear tyrosine kinase c-Abl negatively regulates cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900066-2

7 January 2021

The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900066-2

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900066-2

7 January 2021

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900066-2

7 January 2021

Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900066-2

7 January 2021

The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900066-2

7 January 2021

10.1016/S0145-2126(01)00066-2

Identifiers

DOI

1 reference

26 November 2017

1 reference